Drug Profile
Recombinant erythropoietin - Cadila Pharmaceuticals
Latest Information Update: 04 Dec 2015
Price :
$50
*
At a glance
- Originator Cadila Pharmaceuticals
- Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia